SCYNEXIS (SCYX) AI Stock Analysis

• Market Cap: $28.80M
• Dividend Yield: N/A
• Average Volume (3M): 165.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: -98.13%
• EPS Growth: -129.06%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.11
• Shares Outstanding: 39,020,275
• 10 Day Avg. Volume: 227,442
• 30 Day Avg. Volume: 165,664
• PEG Ratio: 0.05
• Price to Book (P/B): 0.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.06
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 1.02
• Enterprise Value/Gross Profit: 9.58
• Enterprise Value/Ebitda: -0.18
• 1Y Price Target: $4.00
• Price Target Upside: 440.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 43 Neutral
• Price Target: $0.50 ▼(-32.43%Downside)

The overall stock score for SCYNEXIS is driven primarily by significant financial and corporate challenges. The company's financial performance is weak, with negative cash flow and profitability issues. Corporate events highlight a major risk of delisting, which negatively impacts investor confidence. Technical indicators also reflect a bearish outlook, while valuation concerns due to a negative P/E ratio add further pressure.

Positive Factors

Clinical Trials

The FDA clinical hold on the P3 MARIO study of Brexafemme has been lifted, allowing Synexis to resume the study.

Financial Stability

Scynexis has $53M in cash as of the end of 1Q25 which should provide runway into mid-2026, so the MARIO trial can continue.

Product Approval

Brexafemme, the first-in-class triterpenoid antifungal, has broad-spectrum fungicidal activity and is approved for vulvovaginal candidiasis.

Negative Factors

Financial Projections

Lowering the 12-month price target to $4.00, from $8.00, due to ongoing uncertainty with GSK on manufacturing issues related to Brexafemme commercialization.

Partnership Dispute

The dispute between GSK and Scynexis regarding MARIO study milestone payments of $30M continues.

Revenue Risk

Uncertainty around the timelines for Brexafemme commercial royalties and GSK's potential filing for approval in invasive fungal infections increases the revenue risk adjustment to 50%.

SCYNEXIS Business Overview & Revenue Model

Company Description

SCYNEXIS, Inc. (SCYX) is a biopharmaceutical company focused on the research, development, and commercialization of novel anti-infectives to address significant unmet medical needs. The company primarily operates in the healthcare sector, specifically within pharmaceuticals. SCYNEXIS's core product is ibrexafungerp, a novel class of antifungal agents called triterpenoids, designed to treat serious and life-threatening fungal infections. Their expertise lies in developing innovative therapies that can offer new solutions in the treatment of fungal diseases.

How the Company Makes Money

SCYNEXIS generates revenue through the commercialization of its antifungal treatments, particularly ibrexafungerp, which is marketed under the brand name BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC). The company earns money through product sales, licensing agreements, and strategic collaborations with other pharmaceutical companies. Revenue streams also include milestone payments and royalties associated with partnerships. SCYNEXIS's financial performance is significantly influenced by its ability to successfully market its product and expand global partnerships to broaden the reach of its antifungal therapies.

SCYNEXIS Financial Statement Overview

Summary

SCYNEXIS faces significant financial challenges, including declining revenue and profitability, a moderately leveraged balance sheet, and negative cash flow trends. These issues highlight operational inefficiencies and liquidity concerns.

Income Statement

SCYNEXIS shows significant volatility in its revenue and profitability. The revenue decreased sharply in 2024 from the previous year, and the company experienced a substantial net loss. The EBIT and EBITDA margins are negative, indicating operational challenges.

Balance Sheet

The company's balance sheet reflects a moderate debt-to-equity ratio and relatively stable stockholders' equity. However, the equity ratio is low, suggesting a higher reliance on liabilities, which could be risky.

Cash Flow

The cash flow situation is concerning, with negative free cash flow and operating cash flow. The company has not been able to generate positive cash flow from its operations, indicating a potential liquidity issue.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.75M	140.14M	5.09M	13.16M	0.00
Gross Profit	3.75M	124.52M	4.46M	12.85M	-303.00K
EBITDA	-18.58M	73.48M	-59.91M	-31.41M	-51.15M
Net Income	-21.29M	67.04M	-62.81M	-32.87M	-55.19M
Balance Sheet
Total Assets	90.64M	128.41M	87.81M	119.84M	102.54M
Cash, Cash Equivalents and Short-Term Investments	59.30M	74.36M	73.50M	104.48M	93.04M
Total Debt	16.27M	15.08M	48.60M	43.63M	19.84M
Total Liabilities	35.57M	55.45M	84.58M	78.58M	79.78M
Stockholders Equity	55.08M	72.96M	3.23M	41.26M	22.76M
Cash Flow
Free Cash Flow	-24.01M	60.16M	-79.89M	-55.73M	-49.36M
Operating Cash Flow	-24.01M	60.16M	-79.88M	-54.56M	-49.35M
Investing Cash Flow	6.15M	-34.88M	-27.39M	-1.17M	6.47M
Financing Cash Flow	-139.00K	-36.72M	48.60M	67.12M	94.00M

SCYNEXIS Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Neutral. The current price of 0.74 is above the 20-day moving average (MA) of 0.72, below the 50-day MA of 0.79, and below the 200-day MA of 1.05, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.39 is Neutral, neither overbought nor oversold. The STOCH value of 26.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SCYX.

SCYNEXIS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMTI	61 Neutral	$38.28M	―	-2.12%	―	12.82%	96.46%
Sector *	52 Neutral	$7.60B	0.10	-62.94%	2.08%	16.16%	0.34%
SCYX	43 Neutral	$28.80M	―	-43.47%	―	-98.13%	-129.06%
CPHI	43 Neutral	$6.08M	―	-59.14%	―	-33.10%	71.37%
DRRX	40 Underperform	$18.44M	―	-203.11%	―	-41.45%	40.69%
KALA	31 Underperform	$45.17M	―	-576.46%	―	―	38.50%

SCYNEXIS Corporate Events

SCYNEXIS Holds Annual Meeting, Re-elects Directors

On June 25, 2025, SCYNEXIS, Inc. conducted its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and financial oversight. The meeting resulted in the re-election of seven directors, the ratification of Deloitte & Touche LLP as the independent accounting firm for the fiscal year ending December 31, 2025, and the approval of executive compensation as outlined in the company’s proxy statement. These decisions are crucial for SCYNEXIS’s operational continuity and strategic planning, potentially impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (SCYX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.

SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price

On June 20, 2025, SCYNEXIS received a notification from Nasdaq regarding its failure to meet the minimum bid price requirement for its common stock, which has been below $1.00 for 30 consecutive business days. SCYNEXIS has until December 17, 2025, to regain compliance, with options including a reverse stock split if necessary. Failure to comply could result in delisting, although SCYNEXIS may appeal any delisting decision.

The most recent analyst rating on (SCYX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.